Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVF Vaccines HIV vaccine
- Development stage
- Preclinical
- Lead developer
- SVF Vaccines
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
SVF Vaccines HIV vaccine is an experimental vaccine candidate currently in preclinical development for the prevention or treatment of Human Immunodeficiency Virus (HIV) infection. Developed by SVF Vaccines, the candidate utilizes a nucleic acid-based platform that can be configured as either a DNA or mRNA vaccine. The technology is designed to deliver genetic instructions to host cells, prompting the production of viral antigens that trigger a robust immune response against HIV. As of early 2026, the program remains in the discovery and preclinical stages of development.
- Other names
- HIV vaccineSVF HIV vaccine
Beyond the preview
Go deeper on SVF Vaccines HIV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SVF Vaccines HIV vaccine.